Drugs / Bugitinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07563179 | Apr 2026 → Jun 2029 expected | acute myeloid leukemia | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bugitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07563179 ↗ |
| Route | Oral | “Bugitinib orally once daily” NCT07563179 ↗ |